FRAGMIN IN UNSTABLE ANGINA-PECTORIS OR IN NON-Q-WAVE ACUTE MYOCARDIA INFARCTION (THE FRIC STUDY)

The safety and efficacy of weight-adjusted, low-molecular-weight hepar in (dalteparin) was compared with that of unfractionated heparin durin g 6 days of treatment in 1,482 patients with unstable angina or non-Q- wave myocardial infarction, Dalteparin, at a lower dose, was compared with placebo during the following 39 days, No significant outcome diff erence was found between the 2 treatment regimens in the unblinded pha se (days 1-6), Between days 6-45 the rates of death, myocardial infarc tion, and recurrence of angina were comparable between the active trea tment and placebo groups, The results suggest that twice-daily adminis tration of subcutaneous dalteparin may be an effective and safe altern ative to unfractionated heparin during the acute phase of unstable cor onary artery disease, Prolonged treatment with dalteparin at a lower o nce-daily dose did not confer any additional benefit over aspirin (75- 165 mg) alone, (C) 1997 by Excerpta Medica, Inc.